Observational analysis identified NR2F6's role in drug resistance and DNA damage repair in glioblastoma, suggesting novel therapeutic strategies are needed.
Key Points
Temozolomide resistance decreased sensitivity in glioma cells, leading to higher drug resistance rates.
E2F2 and PARP1 upregulation was noted in 648 glioma samples from TCGA and in 325 samples from CGGA.
Analysis was performed using RNA sequencing data and statistical analyses with R language and GraphPad Prism.
Highlighting the significant implications of NR2F6 for improving patient prognosis and chemotherapeutic strategies.